• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Orchestra BioMed Holdings Inc.

    9/9/24 4:48:12 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $OBIO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001402222
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Orchestra BioMed Holdings, Inc.
    SEC File Number
    001-39421
    Address of Issuer
    150 UNION SQUARE DRIVE
    NEW HOPE
    PENNSYLVANIA
    18938
    Phone
    646-343-9298
    Name of Person for Whose Account the Securities are To Be Sold
    Fain Eric S
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    18009773.663782457109/09/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/18/2024Restricted Stock VestingIssuerCheckbox not checked180008/18/2024Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Eric S. Fain
    150 Union Square Drive
    New Hope � PA � 18938
    Common09/06/2024200011279.11

    144: Remarks and Signature

    Remarks
    This sale occurred in the Fain Living Trust account of which Eric Fain is a trustee.
    Date of Notice
    09/09/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Eric Fain

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    2/7/2023$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

      Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval modulation ("AVIM") therapy now includes 46 issued U.S. patents and 91 patents outside the U.S. that collectively comprise over 2100 claims related to the treatment of hypertension as well as heart failureHeart failure pipeline program now protected by an additional 17 issued global patents FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk, including those at risk of heart fa

      5/7/25 8:30:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

      Orchestra BioMed's Virtue® Sirolimus AngioInfusion Balloon™ ("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device DesignationsThe Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis ("ISR")Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SABWith the amended IDE approved by the FDA, Orchestra BioMed is currently targeti

      4/29/25 9:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

      NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: Chardan Capital's Trending Issues in Drug Development Conference – April 29, 2025 (Virtual) David Hochman, Orchestra BioMed's Chairman and Chief Executive Officer, will participate in a fireside chat with Keay Nakae, Senior Research Analyst, Chardan on the topic of "Data & Reg

      4/28/25 4:30:00 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.

      SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      5/1/25 5:41:46 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.

      DEFA14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:18:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.

      DEF 14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:16:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $18,640 worth of shares (4,000 units at $4.66), increasing direct ownership by 0.70% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/26/24 5:46:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P was granted 98,333 shares, increasing direct ownership by 20% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:44:39 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

      The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

      2/18/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:19:57 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:16:55 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

      SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      7/17/24 4:32:50 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Financials

    Live finance-specific insights

    See more
    • Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

      Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

      9/19/23 7:30:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Orchestra BioMed with a new price target

      BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

      3/20/25 8:00:48 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Barclays initiated coverage on Orchestra BioMed with a new price target

      Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00

      1/2/25 8:04:57 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • H.C. Wainwright initiated coverage on Orchestra BioMed with a new price target

      H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

      8/22/24 7:33:07 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care